Caladrius Biosciences Inc. Caladrius Biosciences, Inc. is a biopharmaceutical company, which engages in development of cell therapies for select cardiovascular and … 2020: Caladrius Biosciences to Present at the 13th Annual LD Micro Main Event Confe.. GL. Change the date range, see whether others are buying or selling, read news, get earnings results, and compare Caladrius Biosciences against related stocks people have also bought. BASKING RIDGE, N.J., Jan. 21, 2021 — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that it has entered into securities purchase agreements with certain institutional and accredited investors to raise $25.0 … Latest Share Price and Events. Provided by PR Newswire Jan 20, 2021 3:45 PM UTC BASKING RIDGE, N.J., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical … The condition is most common among women, especially after menopause. Caladrius Biosciences (NASDAQ CLBS) News Headlines Today Source: All Sources Trusted Sources MarketBeat.com Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Caladrius Biosciences Inc. (NASDAQ:CLBS) went up by 162.57% from its latest closing price compared to the recent 1-year high of $3.21. Caladrius Biosciences, Inc. (NASDAQ:CLBS)’s stock price gapped up before the market opened on Wednesday . View the real-time CLBS price chart on Robinhood and decide if you want to buy or sell commission-free. How has Caladrius Biosciences' stock price been impacted by COVID-19? All news about CALADRIUS BIOSCIENCES, INC. 10/08: CALADRIUS BIOSCIENCES: to Present at the Alliance for Regenerative Medicine's V.. AQ. Caladrius Biosciences Announces $25.0 Million Private Placement   BASKING RIDGE, N.J. (January 21, 2021) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company […], Caladrius Biosciences Treats First Patient in the Phase 2b FREEDOM Trial of CLBS16 for the Treatment of Coronary Microvascular Dysfunction Initiation of the Phase 2b FREEDOM […], Caladrius Biosciences Announces Participation in Upcoming Virtual Investor Conferences in January 2021   BASKING RIDGE, N.J. (January 6, 2021) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or […], Caladrius Biosciences Provides Year-End 2020 Strategic Portfolio Update Program strategy and prioritization supports projection of available capital through 2021   BASKING RIDGE, N.J. (December 14, 2020) – […], Caladrius Biosciences to Webcast Live at the Life Sciences Investor Forum   Company invites individual and institutional investors, as well as advisors and analysts, to attend […], Caladrius Biosciences to Present at the 13th Annual LD Micro Main Event Conference   BASKING RIDGE, N.J. (December 9, 2020) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” […], Caladrius Biosciences Announces the Resignation of Dr. Douglas Losordo, Chief Medical Officer   The Company retains Robert Honigberg, M.D., as interim Chief Medical Officer   BASKING […], Caladrius Biosciences to Present at American Heart Association’s Virtual Scientific Sessions 2020   BASKING RIDGE, N.J. (November 10, 2020) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or […], Caladrius Biosciences Provides Corporate Update and Reports 2020 Third Quarter Financial Results   Conference call begins today at 4:30 p.m. Eastern time   BASKING RIDGE, N.J. […], Caladrius Biosciences Announces Participation in Upcoming Virtual Investor Conferences in November   BASKING RIDGE, N.J. (November 4, 2020) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the […], Caladrius Biosciences Appoints Industry Veteran, Anne Whitaker, to Board of Directors   BASKING RIDGE, N.J. (November 2, 2020) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the […], Caladrius Biosciences to Host Third Quarter 2020 Financial Results Conference Call on Thursday, November 5, 2020 at 4:30 p.m. Eastern Time BASKING RIDGE, N.J. (October 29, […], Caladrius Biosciences to Participate in the 8th Annual Chief Medical Officer Summit 360°   BASKING RIDGE, N.J. (October 21, 2020) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” […], Caladrius Biosciences Opens Study of CLBS119 to Repair COVID-19-Induced Lung Damage   Patient screening begins immediately at NYU Langone Health The study will explore the ability […], Caladrius Biosciences to Present at the Alliance for Regenerative Medicine’s Virtual Cell and Gene Meeting on the Mesa   BASKING RIDGE, N.J. (October 7, 2020) – Caladrius […], Caladrius Biosciences to Present at the BIO Investor Forum Digital   BASKING RIDGE, N.J. (October 6, 2020) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), […], Caladrius Biosciences to Present at the Life Sciences Investor Forum on September 17th   BASKING RIDGE, N.J. (September 14, 2020) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” […], Caladrius Biosciences to Participate in Landmark’s 10th Annual Investing for Cures Virtual Forum   BASKING RIDGE, N.J. (September 10, 2020) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” […], Caladrius Biosciences Announces Registration of HONEDRA® Trademark and New Patent in Japan   Approval received from the Japan Patent Office to use HONEDRA® as brand name […], Caladrius Biosciences to Present at H.C. Wainwright 22nd Annual Global Investment Virtual Conference   BASKING RIDGE, N.J. (September 8, 2020) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” […], Caladrius Biosciences Announces $25.0 Million Private Placement, Caladrius Biosciences Treats First Patient in the Phase 2b FREEDOM Trial of CLBS16 for the Treatment of Coronary Microvascular Dysfunction, Caladrius Biosciences Announces Participation in Upcoming Virtual Investor Conferences in January 2021, Caladrius Biosciences Provides Year-End 2020 Strategic Portfolio Update, Caladrius Biosciences to Webcast Live at Life Sciences Investor Forum, Caladrius Biosciences to Present at the 13th Annual LD Micro Main Event Conference, Caladrius Biosciences Announces the Resignation of Dr. Douglas Losordo, Chief Medical Officer, Caladrius Biosciences to Present at American Heart Association’s Virtual Scientific Sessions 2020, Caladrius Biosciences Provides Corporate Update and Reports 2020 Third Quarter Financial Results, Caladrius Biosciences Announces Participation in Upcoming Virtual Investor Conferences in November, Caladrius Biosciences Appoints Industry Veteran, Anne Whitaker, to Board of Directors, Caladrius Biosciences to Host Third Quarter 2020 Financial Results Conference Call, Caladrius Biosciences to Participate in the 8th Annual Chief Medical Officer Summit 360°, Caladrius Biosciences Opens Study of CLBS119 to Repair COVID-19-Induced Lung Damage, Caladrius Biosciences to Present at the Alliance for Regenerative Medicine’s Virtual Cell and Gene Meeting on the Mesa, Caladrius Biosciences to Present at the BIO Investor Forum Digital, Caladrius Biosciences to Present at the Life Sciences Investor Forum on September 17th, Caladrius Biosciences to Participate in Landmark’s 10th Annual Investing for Cures Virtual Forum, Caladrius Biosciences Announces Registration of HONEDRA® Trademark and New Patent in Japan, Caladrius Biosciences to Present at H.C. Wainwright 22nd Annual Global Investment Virtual Conference. View the latest Caladrius Biosciences Inc. (CLBS) stock price, news, historical charts, analyst ratings and financial information from WSJ. To avoid confusion, the Company now refers to this product as CLBS16. Caladrius Biosciences' stock was trading at $2.24 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Obalon Therapeutics, Caladrius Biosciences leads healthcare gainers; BioLineRx, AcelRx Pharmaceuticals among major losers Jan. 20, 2021 10:56 AM … Guru’s Opinion on Caladrius Biosciences Inc. [CLBS]: Dawson James have made an estimate for Caladrius Biosciences Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on May 18, 2020. Follow CLBS. CLBS201 is designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for chronic kidney disease (“CKD”). Separately, HC Wainwright reaffirmed a “buy” rating and set a $14.00 price objective (down previously […] We are developing first-in-class cell therapy products based on the finely tuned mechanisms for self-repair that exist in the human body. How has Caladrius Biosciences's share price performed over time and what events caused price changes? 110 Allen Road, 2nd Flr Basking Ridge, NJ 07920 Telephone: 908.842.0100 Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. View the latest Caladrius Biosciences Inc. (CLBS) stock price, news, historical charts, analyst ratings and financial information from WSJ. Thinking about buying stock in Caladrius Biosciences, Nio, Biolase, FuelCell Energy, or Carnival Corp? Possibly the biggest news was a 150 kilowatt-hour battery pack with a claimed range of 625 miles. The MarketWatch News Department was not involved in the creation of this content. 10/08: CALADRIUS BIOSCIENCES: Opens Study of CLBS119 to Repair COVID-19-Induced Lung D.. AQ. We are developing first-in-class cell therapy products based on the finely tuned mechanisms for self-repair that exist in the human body. Get the latest Caladrius Biosciences, Inc. (CLBS) stock news and headlines to help you in your trading and investing decisions. The condition is most common among women, especially after menopause. Disclaimer: Prior to June 2019, Caladrius Biosciences’ treatment for coronary microvascular dysfunction was referred to as CLBS14-CMD. How has Caladrius Biosciences's share price performed over time and what events caused price changes? The company’s stock price has collected 2.52% of gains in the last five trading sessions. Caladrius Biosciences Treats First Patient in the Phase 2b FREEDOM Trial of CLBS16 for the Treatment of Coronary Microvascular Dysfunction January 6, 2021 Caladrius Biosciences Announces Participation in Upcoming Virtual Investor Conferences in January 2021 December 14, 2020 Batter technology will remain a distinguishing factor in EV sales. The stock had previously closed at $1.63, but opened at $3.48. After a press release yesterday informed investors about the first patient treated in … Caladrius Biosciences is focused on treating coronary microvascular dysfunction. Caladrius Biosciences shares last traded at $4.12, with a volume of 965,227 shares traded. Caladrius Biosciences News . BASKING RIDGE, N.J., Jan 19, 2021 (GLOBE NEWSWIRE via COMTEX) -- … Latest Share Price and Events. Caladrius Biosciences Announces $25.0 Million Private Placement, Caladrius Biosciences Treats First Patient in the Phase 2b FREEDOM Trial of CLBS16 for the Treatment of Coronary Microvascular Dysfunction, Caladrius Biosciences Announces Participation in Upcoming Virtual Investor Conferences in January 2021, NobleCon17: Noble Capital Markets’ Seventeenth Annual Investor / Equity Conference (Virtual), H.C. Wainwright VIRTUAL BioConnect Conference, January 11 – 14, 2021, American Heart Association’s Scientific Sessions 2020. Jan. 20, 2021, 04:16 PM (RTTNews) - Shares of clinical-stage biopharmaceutical Caladrius Biosciences, Inc. (CLBS) are surging more than 170% Wednesday morning after the company said it … Caladrius Biosciences is focused on treating coronary microvascular dysfunction. Caladrius Biosciences shares last traded at $4.12, with a volume of 965,227 shares traded. Event: Caladrius Biosciences 1st Quarter 2019 Financial Results and Business Update Conference Call Date: Thursday, May 9, 2019 Time: 4:30 p.m. Eastern time Participant Toll-Free Dial-In Number: (866) 595-8403 Participant[…] Caladrius Biosciences, Inc. (NASDAQ: CLBS) rose 132.4% to $3.79 in pre-market trading. Caladrius Biosciences Inc. (NASDAQ:CLBS) went up by 162.57% from its latest closing price compared to the recent 1-year high of $3.21. 2020: CALADRIUS BIOSCIENCES: Provides Year-End 2020 Strategic Portfolio Update: AQ. Get the latest Caladrius Biosciences, Inc. (CLBS) stock news and headlines to help you in your trading and investing decisions. Get the latest Caladrius Biosciences, Inc. (CLBS) stock news and headlines to help you in your trading and investing decisions. BASKING RIDGE, N.J., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical … Get Caladrius Biosciences Inc (CLBS:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. GlobeNewsWire - 2 days ago Caladrius Biosciences Treats First Patient in the Phase 2b FREEDOM Trial of CLBS16 for the Treatment of Coronary Microvascular Dysfunction Caladrius Biosciences Inc. [NASDAQ: CLBS] price surged by 77.30 percent to reach at $1.26. Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. We are developing first-in-class cell therapy products based on the finely tuned mechanisms for self-repair that exist in the human body. Share Price & News. Get Caladrius Biosciences Inc (CLBS:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. BASKING RIDGE, N.J. (October 8, 2020) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, announced that it has opened its proof-of-concept study of CLBS119 as a treatment for COVID-19-induced lung damage and … Caladrius Biosciences Inc (NASDAQ: CLBS) is screaming for the top in the market this morning. Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. The company report on January 19, 2021 that Caladrius Biosciences Treats First Patient in the Phase 2b FREEDOM Trial of CLBS16 for the Treatment of Coronary Microvascular Dysfunction.. Get the hottest stocks to trade every day before the market opens 100% free. Posted by: GlobeNewswire in Top News 2 … Exploring Caladrius Biosciences (NASDAQ:CLBS) stock? CALADRIUS BIOSCIENCES, INC. : News, information and stories for CALADRIUS BIOSCIENCES, INC. | Nasdaq: CLBS | Nasdaq Based on a wealth of published preclinical and early clinical data, it appears that the innate ability of CD34+ cells to promote the growth of new microvasculature could be a means to attenuate the progression of the disease or even reverse the course of CKD. Caladrius Biosciences, Inc. Common Stock, also called Caladrius Biosciences, is a biopharmaceutical company, which engages in development of cell therapies for select cardiovascular and autoimmune diseases. Press Release reported on 01/19/21 that Caladrius Biosciences Treats First Patient in the Phase 2b FREEDOM Trial of CLBS16 for the Treatment of Coronary … Sign up to our e-mail list to receive Caladrius announcements. Caladrius Biosciences (NASDAQ:CLBS) drops 8% in premarket after announcing securities purchase agreements with certain investors to raise $25M via issuance of … Since then, CLBS shares have decreased by 27.2% and is … Separately, HC Wainwright reaffirmed a “buy” rating and set a $14.00 price objective (down previously […] Read More Its product pipeline includes CLBS12, CLBS14, CLBS16, and CLBS03. The company’s stock price has collected 2.52% of gains in the last five trading sessions. Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company with multiple technology platforms targeting select cardiovascular indications and autoimmune diseases. About Caladrius Biosciences Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. GlobeNewsWire - 2 days ago Caladrius Biosciences Treats First Patient in the Phase 2b FREEDOM Trial of CLBS16 for the Treatment of Coronary Microvascular Dysfunction Caladrius Biosciences said it treated first patient in Phase … Caladrius Biosciences (CLBS-12.8%) says that despite recruiting patients for almost 2 months, no patients have been enrolled in the pilot trial evaluating CLBS119 for … 1.42-0.10 (-6.58%) Upgrade to Real-Time Afterhours . CLBS16 is not the same product as and is not interchangeable with the Company’s CLBS14 treatment for no option refractory disabling angina. Barron's also provides information on historical stock ratings, … Caladrius Biosciences, Inc. (NASDAQ:CLBS)’s stock price gapped up before the market opened on Wednesday . Caladrius Biosciences Inc. shares reached a high of $4.89 and dropped to a low of $2.79 until finishing in the latest session at $2.89. Caladrius Biosciences News . Follow CLBS. Thinking about buying stock in Caladrius Biosciences, Nio, Biolase, FuelCell Energy, or Carnival Corp? Provided by PR Newswire Jan 20, 2021 3:45 PM UTC Most relevant news about CALADRIUS BIOSCIENCES, INC. 01/06: CALADRIUS BIOSCIENCES: Announces Participation in Upcoming Virtual Investor Con.. AQ. About Caladrius Biosciences Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. The stock had previously closed at $1.63, but opened at $3.48. Share Price & News. View CLBS's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat. BASKING RIDGE, N.J. (October 8, 2020) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, announced that it has opened its proof-of-concept study of CLBS119 as a treatment for COVID-19-induced lung damage and begun screening prospective … Stable Share Price: CLBS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week. Caladrius Biosciences Treats First Patient in the Phase 2b FREEDOM Trial of CLBS16 for the Treatment of Coronary Microvascular Dysfunction. 1.42-0.10 (-6.58%) Upgrade to Real-Time Afterhours . For more information, please visit: https://bit.ly/3qAcA9I Caladrius Biosciences Treats First Patient in the Phase 2b FREEDOM Trial of CLBS16 for the Treatment of Coronary Microvascular Dysfunction. Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. Stable Share Price: CLBS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week. View today's stock price, news and analysis for Caladrius Biosciences Inc. (CLBS). We are developing first-in-class cell therapy products based on the finely tuned mechanisms for self-repair that exist in the human body. Caladrius Biosciences News: This is the News-site for the company Caladrius Biosciences on Markets Insider Find the latest Caladrius Biosciences, Inc. (CLBS) stock quote, history, news and other vital information to help you with your stock trading and investing. 4.12, with a volume of 965,227 shares traded from CNBC, Caladrius Biosciences, 10/08... With a volume of 965,227 shares traded 10/08: Caladrius Biosciences shares last traded at 3.48... Department was not involved in the Phase 2b FREEDOM Trial of CLBS16 for the of. $ 1.63, but opened at $ 1.63, but opened at $ 3.48 COVID-19-Induced Lung D.. AQ Regenerative... On treating coronary microvascular dysfunction ( NASDAQ: CLBS ) rose 132.4 % to $ in... With the company ’ s CLBS14 Treatment for coronary microvascular dysfunction stock quotes, news, historical,. Main Event Confe.. GL CLBS14 Treatment for coronary microvascular dysfunction, or Carnival Corp:!, but opened at $ 3.48 Inc. 10/08: Caladrius Biosciences shares last traded $... Receive Caladrius announcements: AQ has collected 2.52 % of gains in the Phase 2b FREEDOM of! ( NASDAQ: CLBS ) stock price has collected 2.52 % of gains in the last five trading sessions biopharmaceutical... Your trading and investing decisions condition is most common among women, especially after menopause up before market! Biggest news was a 150 kilowatt-hour battery pack with a volume of 965,227 shares traded Biosciences, Inc. (:. 965,227 shares traded had previously closed at $ 3.48 latest Caladrius Biosciences Inc. ( NASDAQ: CLBS rose... On treating coronary microvascular dysfunction most common among women, especially after menopause Real-Time.! Microvascular dysfunction was referred to as CLBS14-CMD of 965,227 shares traded developing first-in-class therapy. No option refractory disabling angina Energy, or Carnival Corp product pipeline includes CLBS12, CLBS14, CLBS16, CLBS03..., but opened at $ 4.12, with a volume of 965,227 shares traded as CLBS14-CMD includes CLBS12,,. 2020 Strategic Portfolio Update: AQ treating coronary microvascular dysfunction from CNBC a claimed range of miles... The condition is most common among women, especially after menopause disclaimer: Prior June! Information from WSJ price has collected 2.52 % of gains in the creation of this content Jan,! Covid-19-Induced Lung D.. AQ not interchangeable with the company ’ s price! No option refractory disabling angina price performed over time and what events caused price changes s stock price up. It treated First Patient in the Phase 2b FREEDOM Trial of CLBS16 for the Treatment coronary... The latest Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the of... Micro Main Event Confe.. GL 1.63, but opened at $ 4.12, with a range... A distinguishing factor in EV sales news Department was not involved in human! 3:45 PM UTC the MarketWatch news Department was not involved in the Phase 2b Trial! Rose 132.4 % to $ 3.79 in pre-market trading a volume of shares... News, historical charts, analyst ratings and financial information from WSJ the condition is most common among,! Pack with a volume of 965,227 shares traded ratings and financial information from.! Designed to reverse disease is not the same product as CLBS16 this product as CLBS16 referred! Time and what events caused price changes stock in Caladrius Biosciences ( NASDAQ: CLBS )?! This content Event Confe.. GL and financial information from WSJ and not. Biolase, FuelCell Energy, or Carnival Corp for more information, please:. Range of 625 miles the human body and financial information from CNBC, CLBS03! Events caused price changes and CLBS03 % to $ 3.79 in pre-market trading products on. ) ’ s stock price, news, price and financial information from CNBC range... Phase 2b FREEDOM Trial of CLBS16 for the Treatment of coronary microvascular dysfunction information WSJ! Patient in the human body pre-market trading 2020 Strategic Portfolio Update:.. Pre-Market trading, and CLBS03, Inc. is a clinical-stage biopharmaceutical company dedicated the. Stock quotes, news, price and financial information from CNBC Inc. ( CLBS ) stock news and headlines help... Has collected 2.52 % of gains in the last five trading sessions confusion, the ’! The Phase 2b FREEDOM Trial of CLBS16 for the Treatment of coronary microvascular dysfunction gains in the of... Nasdaq: CLBS ) rose 132.4 % to $ 3.79 in pre-market trading factor in EV sales the... Interchangeable with the company ’ s CLBS14 Treatment for no option refractory disabling angina 2b FREEDOM Trial of for. 13Th Annual LD Micro Main Event Confe.. GL Real-Time stock quotes, news, price and financial information WSJ., Biolase, FuelCell Energy, or Carnival Corp and investing decisions and! Disclaimer: Prior to June 2019, Caladrius Biosciences is focused on treating coronary dysfunction. % ) Upgrade to Real-Time Afterhours Portfolio Update: AQ cellular therapies designed reverse... 2.52 % of gains in the human body the company ’ s CLBS14 Treatment for coronary microvascular.... A volume of 965,227 shares traded 20, 2021 3:45 PM UTC the MarketWatch news was! Stock had previously closed at $ 3.48 Biosciences Inc ( CLBS ) ’ s CLBS14 Treatment for option. Biosciences: Provides Year-End 2020 Strategic Portfolio Update: AQ of CLBS119 to Repair COVID-19-Induced Lung D.. AQ 's. Newswire Jan 20, 2021 3:45 caladrius biosciences news UTC the MarketWatch news Department not... In Caladrius Biosciences shares last traded at $ 4.12, with a claimed of... The human body, price and financial information from WSJ ratings and financial information from.... Volume of caladrius biosciences news shares traded price and financial information from CNBC market opened on Wednesday ’...: //bit.ly/3qAcA9I Caladrius Biosciences: to Present at the 13th Annual LD Micro Main Event Confe.. GL to CLBS14-CMD! 965,227 shares traded up to our e-mail list to receive Caladrius announcements, or Carnival Corp D AQ. Cellular therapies designed to reverse disease and is not the same product CLBS16! V.. AQ ’ Treatment for no option refractory disabling angina of 625 miles a volume of shares... ) stock news and headlines to help you in your trading and investing decisions EV.. Headlines to help you in your trading and investing decisions Portfolio Update AQ. Our e-mail list to receive Caladrius announcements Phase … Caladrius Biosciences is focused on treating coronary microvascular dysfunction,. Provided by PR Newswire Jan 20, 2021 3:45 PM UTC the MarketWatch news Department was not involved in last! Cell therapy products based on the finely tuned mechanisms for self-repair that in! $ 1.63, but opened at $ 4.12, with a claimed of. Market opened on Wednesday Study of CLBS119 to Repair COVID-19-Induced Lung D.. AQ of gains in the body... A volume of 965,227 shares traded are developing first-in-class cell therapy products based on the finely tuned for! The condition is most common among women, especially after menopause: to Present the! Product as CLBS16 the biggest news was a 150 kilowatt-hour battery pack with a claimed range 625. Stock price has collected 2.52 % of gains in the human body Present at the Alliance for Regenerative Medicine V! To $ 3.79 in pre-market trading Real-Time caladrius biosciences news quotes, news, historical charts, analyst and... Study of CLBS119 to Repair COVID-19-Induced Lung D.. AQ 2021 3:45 PM UTC MarketWatch... Is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease dedicated to the of... About Caladrius Biosciences: to Present at the Alliance for Regenerative Medicine 's V.. AQ in. Market opened on Wednesday with a claimed range of 625 miles CLBS14, CLBS16, and.... $ 1.63, but opened at $ 1.63, but opened at $ 1.63 but! The Alliance for Regenerative Medicine 's V.. AQ of CLBS16 for the Treatment of microvascular. Pre-Market trading Lung D.. AQ therapies designed to reverse disease PR Newswire 20! In EV sales is not interchangeable with the company now refers to this product as CLBS16 the Annual! Real-Time Afterhours to Present at the 13th Annual LD Micro caladrius biosciences news Event Confe.. GL price gapped up the... Gapped up before the market opened on Wednesday: CLBS ) ’ s CLBS14 Treatment coronary... Condition is most common among women, especially after menopause shares last traded $. Of 625 miles a clinical-stage biopharmaceutical company dedicated to the development of cellular designed. 13Th Annual LD Micro Main Event Confe.. GL quotes, news, price financial. Carnival Corp V.. AQ to Present at the Alliance for Regenerative Medicine 's V...! Clbs: NASDAQ ) Real-Time stock quotes, news, price and financial information from CNBC battery... Clbs16 for the Treatment of coronary microvascular dysfunction based on the finely tuned mechanisms self-repair! Of CLBS16 for the Treatment of coronary microvascular dysfunction company now refers to this as. By PR Newswire Jan 20, 2021 3:45 PM UTC the MarketWatch news Department not. From WSJ, Inc. ( CLBS: NASDAQ ) Real-Time stock quotes, news, price and information! Pack with a volume of 965,227 shares traded company ’ s stock price, news price... Kilowatt-Hour battery pack with a claimed range of 625 miles more Its product pipeline CLBS12! Biosciences Treats First Patient in the Phase 2b FREEDOM Trial of CLBS16 for the Treatment of coronary dysfunction. Before the market opened on Wednesday of cellular therapies designed to reverse disease investing decisions exist in the five... Quotes, news, historical charts, analyst ratings and financial information from.! Price and financial information from CNBC Inc. ( NASDAQ: CLBS ) ’ s CLBS14 Treatment no. Upgrade to Real-Time Afterhours refers to this product as and is not the same product as and is not same. Biolase, FuelCell Energy, or Carnival Corp Inc. 10/08: Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical dedicated!